Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues for 2022. Revenue growth in 2022 was dramatic, increasing over 60% over 2021 revenue.
“We are pleased with Kurin’s success, as demonstrated by the impressive growth over 2021, which also saw a large revenue increase over the prior year,” said Bob Rogers, CEO of Kurin, Inc. “Our fourth quarter revenue reflected our highest sales quarter by some distance and we are very well positioned for continued strong growth in 2023.”
“In addition, we continue to roll out our proprietary Advance™ push-button needle, providing vertical integration that increases our shareholder value,” said Mr. Rogers. “We continue to build upon the company’s strong financial position and have accelerated our hiring to accommodate this growth.”
Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.